MedTrace Logo

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

NCT07294235 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-12-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.

Conditions

  • Overweight or Obesity

Interventions

DRUG

BGM1812

AdministeredSC

DRUG

Placebo

Administered SC

DRUG

BGM1812

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

  • BrightGene Pharmaceutical Co., Ltd.

    collaborator UNKNOWN

  • BrightGene Bio-Medical Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-05
Primary Completion
2026-03-02
Completion
2026-03-02
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294235 on ClinicalTrials.gov